A Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01)
Clinical trial NCT06941272 · RECRUITING
Trial details
- NCT number
- NCT06941272
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-05-26
- Primary completion
- 2030-12-30
- Enrollment
- 50
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.